Medicine and Dentistry
Neoplasm
92%
Antibody-Drug Conjugate
50%
Triple Negative Breast Cancer
33%
Melanoma
33%
Breast Cancer
30%
Monoclonal Antibody
25%
Immunotherapy
22%
Cytotoxic T-Cell
20%
Ovarian Cancer
19%
Cyclin-Dependent Kinase
16%
Cancer Therapy
16%
Folate Receptor 1
16%
Zirconium 89
16%
B Cell
16%
B Lymphocyte
16%
Epidermal Growth Factor Receptor
16%
Cancer Growth
16%
Monotherapy
16%
Natural Killer Cell
16%
Biological Product
16%
Cancer Grading
16%
Positron Emission Tomography
16%
Immunosuppressive Drug
16%
Repolarization
16%
Cell Interaction
16%
Immunoglobulin E Antibody
16%
Macrophage
16%
Immune Response
15%
T Cell
15%
Immunoglobulin E
13%
Rituximab
11%
Immune-Related Adverse Events
10%
Trastuzumab
9%
Tumor Cell
8%
Immune Checkpoint Inhibitor
8%
Programmed Death 1 Receptor
8%
Pembrolizumab
8%
Ipilimumab
8%
Nivolumab
8%
Immunocompetent Cell
7%
Malignant Neoplasm
7%
Transcriptomics
6%
Cancer Cell
6%
Breast Tumor
6%
Hematological Cancer
5%
Clinical Management
5%
Cancer
5%
Vascularity
5%
Non-Hodgkin Lymphoma
5%
Humoral Immunity
5%
Immunology and Microbiology
Immunoglobulin E
100%
B Cell
53%
Monoclonal Antibody
50%
Immunoglobulin E Antibody
39%
Chondroitin Sulfate Proteoglycan
36%
Immunotherapy
34%
Melanoma Antigen
33%
Antibody Drug Conjugate
33%
Trastuzumab
26%
Gamma Urogastrone
23%
Therapeutic Antibodies
20%
Glycan
18%
Tumor-Associated Macrophage
16%
Immunosurveillance
16%
Natural Killer Cell
16%
Immune System
16%
Glycosylation
16%
Biological Product
16%
positron emission tomographic scan
16%
Immunocompetent Cell
15%
Macrophage
14%
T Cell
12%
Immune Response
12%
Xenograft
12%
Effector Cell
11%
Rituximab
11%
Cancer Cell
10%
Humoral Immunity
10%
Fc Receptor
10%
Tumor Cell
9%
Antibody-Dependent Cell-Mediated Cytotoxicity
9%
Isotype
8%
Antineoplastic Activity
6%
Basophil
6%
Immunology
6%
Degranulation
6%
Prevalence
5%
Vascularization
5%
Avelumab
5%
Cytokine
5%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
68%
Antibody Drug Conjugate
66%
Malignant Neoplasm
62%
Drug Repositioning
50%
Breast Cancer
28%
Disease Association
27%
Epidermal Growth Factor Receptor
16%
Immunoglobulin E
16%
Triple Negative Breast Cancer
16%
Cancer Growth
16%
Folate Receptor 1
16%
Cancer Grading
16%
Cyclin Dependent Kinase
16%
Monoclonal Antibody
16%
Biological Product
16%
Drug Induced Disease
16%
Drug Discovery
16%
Drug Interaction
16%
Biological Marker
16%
Rituximab
11%
Chemotherapy
6%
Nonhodgkin Lymphoma
5%
Trastuzumab
5%
Cetuximab
5%
Cyclin Dependent Kinase Inhibitor
5%
